Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to 13.74%.

  • Organogenesis Holdings' EBITDA Margin rose 83200.0% to 13.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.8%, marking a year-over-year increase of 10100.0%. This contributed to the annual value of 0.27% for FY2024, which is 31600.0% down from last year.
  • As of Q3 2025, Organogenesis Holdings' EBITDA Margin stood at 13.74%, which was up 83200.0% from 12.45% recorded in Q2 2025.
  • Organogenesis Holdings' EBITDA Margin's 5-year high stood at 19.15% during Q2 2021, with a 5-year trough of 30.85% in Q1 2025.
  • For the 5-year period, Organogenesis Holdings' EBITDA Margin averaged around 3.18%, with its median value being 7.42% (2023).
  • Per our database at Business Quant, Organogenesis Holdings' EBITDA Margin surged by 367400bps in 2021 and then tumbled by -273500bps in 2025.
  • Over the past 5 years, Organogenesis Holdings' EBITDA Margin (Quarter) stood at 15.45% in 2021, then plummeted by -51bps to 7.55% in 2022, then crashed by -117bps to 1.27% in 2023, then soared by 734bps to 8.07% in 2024, then soared by 70bps to 13.74% in 2025.
  • Its last three reported values are 13.74% in Q3 2025, 12.45% for Q2 2025, and 30.85% during Q1 2025.